Biomarkers for Traumatic Brain Injury

Table of Contents

Section I. INTRODUCTION
1. Introduction-scope of the problem
2. The need for traumatic brain injury markers
3. Regulatory considerations for diagnostics and biomarkers of traumatic brain injury
Section II. PATHOPHYSIOLOGY OF TBI
4. Peripheral markers of TBI and blood-brain barrier disruption
5. The role of autoimmunity after traumatic brain injury
6. Traumatic brain injury: glial fibrillary acidic protein posttranslational
modification
SECTION III. TBI BIOMARKERS IN MEDICAL PRACTICE
7. Economics of traumatic brain injury biomarkers
8. Electrophysiology monitoring
9. Traumatic brain injury therapeutics
SECTION IV. CLASSICAL TBI BIOMARKERS
10. S100 biomarkers in patients with traumatic brain injury
11. Pathophysiology and clinical implementation of traumatic brain injury biomarkers: neuron-specific enolase
12. Traumatic brain injury biomarkers glial fibrillary acidic protein/ubiquitin C-terminal hydrolase L1
13. Neurofilaments light chain/Neurofilaments heavy chain
14. Tau protein, biomarker for traumatic brain injury
SECTION V. NOVEL TBI BIOMARKERS
15. Neurogranin
16. Myelin basic protein in traumatic brain injury
SECTION VI. ANALYTICAL TESTING CONSIDERATION
17. Antibody selection, evaluation, and validation for analysis of traumatic brain injury biomarkers
18. Sensitive immunoassay testing platforms
19. Clinical mass spectrometry and its applications in traumatic brain injuries
20. Surface plasmon resonance
21. Point-of-care testing for concussion and traumatic brain injury
SECTION VII. NON-BLOOD TBI BIOMARKER STRATEGY
22. Clinical risk factors of traumatic brain injury
23. Saliva biomarkers of traumatic brain injury
24. Digital neurocognitive testing
25. Electroencephalographic as a biomarker of concussion
26. Neuropsychological testing
27. Outpatient risk stratification for traumatic brain injury
28. Peptidomics and traumatic brain injury: biomarker utilities for a theragnostic approach
29. Autoantibodies in central nervous system trauma: new frontiers for diagnosis and prognosis biomarkers

Authors

Alan H.B. Wu Professor of Laboratory Medicine, School of Medicine, San Francisco, CA, USA. Dr. Alan Wu is a Professor of Laboratory Medicine at the University of California at San Francisco. He is the Co-Director of the Core Laboratory at the Zuckerberg San Francisco General Hospital. His research is focused on biomarkers of cardiovascular disease, clinical toxicology, and pharmacogenomics. In this capacity, his clinical and research laboratory conducts testing for routine analytes in blood, urine and cerebral spinal fluid for electrolytes, metabolites, hormones, proteins, and biomarkers. His particular area of interest is in cardiac biomarkers for acute cardiac diseases. He received a B.S. in both Chemistry and Biology at Purdue University and a Ph.D. in Analytical Chemistry at the University of Illinois. He was a professor at the University of Texas and the University of Connecticut prior to his current position at UCSF. W. Frank Peacock Professor, Vice Chair for Research, Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA. W. Frank Peacock IV, MD, FACEP, FACC is a Professor of Emergency Medicine and Vice Chair for Research in the department of Emergency Medicine at Baylor College of Medicine, in Houston, Texas. He has >500 publications, is a two-time winner of the Best Research Paper of the Year Award from the American College of Emergency Physicians, and the 2019 Ray Bahr Award for Excellence from the American College of Cardiology. Finally, he is the founder of Comprehensive Research Associates, LLC, and Emergencies in Medicine, LLC.